Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature

被引：5

作者：

Shibata, Osamu ^{[1
]}

Kamimura, Kenya ^{[1
]}

Ko, Masayoshi ^{[1
]}

Sakai, Norihiro ^{[1
]}

Abe, Hiroyuki ^{[1
]}

Morita, Shinichi ^{[1
]}

Mizusawa, Takeshi ^{[1
]}

Sato, Hiroki ^{[1
]}

Sakamaki, Akira ^{[1
]}

Terai, Shuji ^{[1
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 11期

关键词：

hepatocellular carcinoma; FGFR4; FGF19; lenvatinib; molecular targeting agents; CANCER; ANGIOGENESIS; SORAFENIB; FGF19; INHIBITOR; PROGNOSIS; XENOGRAFT;

D O I：

10.2169/internalmedicine.6580-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma (HCC) cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response to sorafenib. The tumor showed a high expression of fibroblast growth factor receptor 4, which is reportedly related to the sensitivity to lenvatinib in vitro. The information obtained from this case and from our literature review highlights the importance of assessing the expression of the molecules involved in tumors for effective precision medicine.

引用

页码：1709 / 1715

页数：7

共 36 条

[1] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[2]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[3] Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma [J].

Bruix, Jordi ;

Reig, Maria ;

Sherman, Morris .

GASTROENTEROLOGY, 2016, 150 (04) :835-853

[4] Molecular and histological correlations in liver cancer [J].

Calderaro, Julien ;

Ziol, Marianne ;

Paradis, Valerie ;

Zucman-Rossi, Jessica .

JOURNAL OF HEPATOLOGY, 2019, 71 (03) :616-630

[5] Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib [J].

Chen, D. ;

Zhao, P. ;

Li, S. -Q. ;

Xiao, W. -K. ;

Yin, X. -Y. ;

Peng, B. -G. ;

Liang, L. -J. .

EJSO, 2013, 39 (09) :974-980

[6]

Cheng AL, ESMO AS C

[7] Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models [J].

Desnoyers, Lr ;

Pai, R. ;

Ferrando, Re ;

Hotzel, K. ;

Le, T. ;

Ross, J. ;

Carano, R. ;

D'Souza, A. ;

Qing, J. ;

Mohtashemi, I. ;

Ashkenazi, A. ;

French, Dm .

ONCOGENE, 2008, 27 (01) :85-97

[8]

European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019

[9]

Finn RS, 2017, ANN ONCOL, V28, pV605, DOI DOI 10.1093/ANNONC/MDX440.022

[10]

Finn RS, 2018, ANN ONCOL, V29, pVIII17

← 1 2 3 4 →